Modern possibilities of application <sup>99m</sup>Tc-labeled prostate-specific membrane antigen ligands in prostate cancer-Reference-Cited by-同舟云学术

Modern possibilities of application <sup>99m</sup>Tc-labeled prostate-specific membrane antigen ligands in prostate cancer

Published:2022-02-10 Issue:4 Volume:17 Page:136-150
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Leontyev A. V.¹^ORCID,Khalimon A. I.¹^ORCID,Kuliev M. T.¹^ORCID,Govaleshko A. Y.¹^ORCID,Kaprin A. D.²^ORCID,Krasheninnikov A. A.¹^ORCID,Nyushko K. M.³^ORCID,Kalpinskiy A. S.¹^ORCID,Alekseev B. Ya.⁴^ORCID

Affiliation:

1. P.A. Hertzen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

2. National Medical Research Radiological Center, Ministry of Health of Russia

3. P.A. Hertzen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of Russia; Medical Institute of Continuing Education, Moscow State University of Food Production; N.A. Lopatkin Research Institute of Urology and Interventional Radiology — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

4. National Medical Research Radiological Center, Ministry of Health of Russia; Medical Institute of Continuing Education, Moscow State University of Food Production

Abstract

This article presents a modern possibilities and future path of prostate-specific membrane antigen (PSMA) radiopharmacuticals labeled by 99mTc, that is the most popular isotope using in conventional nuclear medicine. The main advantages and disadvantages of SPECT/CT with these radiopharmaceuticals in different phases of prostate cancer continuum have been analyzed. Results of research diagnostic sensitivity of 99mTc-PSMA SPECT/CT including comparison with 68Ga-PSMA PET/CT and conventional modality such as MRI and bone scan are presented. The prerequisites of application 99mTc-labeled PSMA ligands in PSMA-guided surgery, methodology of PSMA-guided surgery and foreign authors application experience are presented in this article too.

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference54 articles.

1. Malignant tumors in Russia in 2019 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, A.O Shachzadova. Moscow: MNIOI im. P.A. Gertsena -filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 239 p. (In Russ.).

2. Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).33. DOI: 10.18027/2224-5057-2020-10-3s2-33.

3. Israeli R.S., Powell C.T., Fair W.R., Heston W.D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53(2):227-30.

4. Silver D.A., Pellicer I., Fair W.R. et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3(1):81-5.

5. Barinka C., Sacha P., Sklenar J. et al. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 2004;13 (6):1627-35. DOI: 10.1110/ps.04622104.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 99mTc-Labelled Low Molecular Weight Inhibitors of Prostate-Specific Membrane Antigen;Annals of the Russian academy of medical sciences;2023-02-04